NSAID Therapy Comparison

Efficacy and Safety

Diclofenac shows superior early pain control compared to both ibuprofen and other NSAIDs for acute musculoskeletal injuries, particularly at days 1 and 2 for mild-to-severe ankle sprains 1
Celecoxib provides equivalent efficacy to both diclofenac and ibuprofen for chronic inflammatory conditions including rheumatoid arthritis and osteoarthritis 2, 3
All NSAIDs carry cardiovascular thrombotic risk, but the relative increase appears similar across agents, with higher absolute risk in patients with known cardiovascular disease 4

The annual risk of serious GI bleeding from chronic NSAID use ranges from 1 in 2,100 in adults under 45 to 1 in 353 in adults 65 and older 5
Up to 30% of high-risk patients developed renal adverse events including hypertension, fluid retention, and renal failure with either celecoxib or diclofenac plus PPI combinations 2, 3, 6

Ibuprofen, but not diclofenac or celecoxib, interferes with aspirin's antiplatelet effect by blocking irreversible acetylation of platelet COX-1 4
Concomitant aspirin use increases GI bleeding risk 5-6 times compared to anticoagulants alone and may reduce the gastroprotective benefits of COX-2 inhibitors 5

First-line: Topical diclofenac with or without menthol gel provides superior early pain relief with minimal systemic absorption for acute musculoskeletal injuries 1, 7
Preferred: Celecoxib 100-200 mg twice daily offers equivalent anti-inflammatory efficacy with significantly better GI tolerability than diclofenac or ibuprofen for chronic inflammatory conditions 2

For high-risk patients, such as those with prior ulcer bleeding, age >65, or anticoagulant use, neither celecoxib alone nor ibuprofen with a proton pump inhibitor provides adequate protection, with recurrent bleeding rates remaining 10-13% annually, according to the Alimentary Pharmacology and Therapeutics journal 8, 9
The American Gastroenterological Association does not provide specific recommendations for high-risk patients taking celecoxib or ibuprofen, however, it is suggested that NSAIDs should be avoided entirely if possible, and consider short-term corticosteroids for acute flares 9
If chronic NSAID therapy is absolutely required for high-risk patients, using celecoxib plus misoprostol plus a proton pump inhibitor may be considered, although this remains unproven, as stated in the Alimentary Pharmacology and Therapeutics journal 9